News & Comments

The FDA Approves Keytruda for Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL   - This is the 2nd indication for Keytruda for a hematologic malignancy. - The approval is based on tumor response rate …

AstraZeneca and Genentech Checkpoint Inhibitors Improve Survival in Two Different Lung Cancers

ASTRAZENECA AstraZeneca's (AZN) Checkpoint Inhibitor Imfinzi significantly improved Overall Survival (OS) for Stage III Non-Small Cell Cancer Imfinzi (durvalumab) achieved positive overall survival …

CARA Therapeutics Has Good News

Cara Therapeutics (CARA) develops novel and proprietary class of product candidates, led by Korsuva (CR845/difelikefalin) injection. This product is a first-in-class peripheral kappa opioid receptor …

 

Today’s Highlights

Why FDA Approval of Agilent Technologies’ Assay is Important to Cervical Cancer Patients

The U.S. Food and Drug Administration (FDA) has approved Agilent Technologies’ (NYSE: A) Dako PD-L1 IHC 22C3 pharmDx assay for an expanded use. The …

CRISPR Editing and the Two Published Studies

Slashing of the CRISPR gene editing companies' stocks, including CRISPR Therapeutics (CRSP), Editas (EDIT) and Intellia (NTLA) is caused by two …

More Promising News for Array from Its Melanoma Combination Clinical Trial

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed that the …

About Nektar’s Product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was …

Recent Popular Posts:

Why FDA Approval of Agilent Technologies’ Assay is Important to Cervical Cancer Patients

The U.S. Food and Drug Administration (FDA) has approved Agilent Technologies’ (NYSE: A) Dako PD-L1 IHC 22C3 pharmDx assay for an expanded use. The expended use is expected to help physicians to identify cervical …

The FDA Approves Keytruda for Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL   - This is the 2nd indication for Keytruda for a hematologic malignancy. - The approval is based on tumor response rate and durability of …

Top